Cetuximab biobetter - Mabtech/Sorrento

Drug Profile

Cetuximab biobetter - Mabtech/Sorrento

Alternative Names: STI-001

Latest Information Update: 14 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mabtech
  • Developer Mabtech Limited
  • Class Antineoplastics; Biobetters; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Colorectal cancer

Most Recent Events

  • 29 Jun 2017 Taizhou Mabtech Pharmaceutical plans a phase III trial for Colorectal cancer (Metastatic disease, Combination therapy, First-line therapy) in China (IV) (NCT03206151)
  • 11 Jan 2016 Efficacy and safety data from a phase III trial in Colorectal cancer released by Sorrento Therapeutics
  • 03 Aug 2015 Mabtech announces intention to submit NDA to Chinese FDA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top